Abstract: A vehicle control apparatus and a vehicle control system including the same are provided. The vehicle control apparatus includes an electronic control unit and a gateway. The electronic control unit is configured to store software identification management information associated with the electronic control unit. The gateway is configured to store a master list of the software identification management information, which includes the software identification management information received from the electronic control unit, deliver update information related to software associated with vehicle type approval (VTA) to the electronic control unit corresponding to the update information, as the update information is received, and update the software identification management information associated with the electronic control unit in the master list as an update of the software of the electronic control unit is completed.

Abstract: A display apparatus may include a plurality of pixels in a display area and a pixel comprises a plurality of sub-pixels, a plurality of first electrodes that extend in a first direction and are between the sub-pixels, a connection electrode between the plurality of first electrodes and configured to transmit a voltage, and a second electrode connected to the connection electrode and configured to apply the voltage to the plurality of sub-pixels.

Abstract: The present invention relates to a compound showing an excellent agonistic activity for a melanocortin receptor and, more specifically, to the compound of chemical formula 1, a pharmaceutical composition containing same as an active ingredient, and a use thereof. In detail, the compound of the present invention exhibits an excellent agonistic activity for melanocortin-4 receptor and thus, can be advantageously used especially for preventing or treating obesity, diabetes, inflammation, and impotence.

Abstract: The present invention relates to uses of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof for the purpose of preventing or treating rare genetic obesity diseases, particularly rare genetic obesity diseases associated with a damaged melanocortin-4 receptor (MC4R) pathway.

Abstract: The present invention relates to use of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof as a selective agonist of the melanocortin-4-receptor (MC4R).

Abstract: The present invention relates to a compound exhibiting excellent agonist activity against melanocortin receptors. More specifically, the present invention relates to a compound of Formula 1, a pharmaceutical composition comprising the compound as an active ingredient, and a use thereof, and the compound of the present invention exhibits excellent agonist activity against melacortin-4 receptors and can be particularly useful in preventing or treating obesity, diabetes, inflammation and erectile dysfunction.